17 Million for Future Cancer Diagnoses

07-Aug-2019 - Germany

After a successful market entry in the DACH Region (Germany, Austria and Switzerland) and the opening of a subsidiary office in Krakow, Poland, inveox continues to grow. With its largest investment so far of 17 million euros, the Munich startup will begin the series-level production of their AI-supported automation system in order to make cancer diagnoses faster and more reliable. 

inveox GmbH

It all began with an idea: to help people by significantly improving the reliability of cancer diagnoses. To the founders, concepts like digitalization, automation and artificial intelligence also belong in the world of histopathology. These have the potential to enable faster and safer cancer diagnoses by enhancing the arrival and processing of tissue samples in a lab. Four business angels believed in this vision, and in 2017 they supported the founders with an investment of 1 million euros. In the summer of 2018 there was a growth investment of 5 million from the same investors. To Managing Partner Dominik Sievert, the most recent investment means more than financial support: “the investors believe in us because inveox has displayed unprecedented strong growth in just a short time. They believe in our product, our leadership and our vision, and more importantly they provide us with an invaluable asset beyond the investment: mentoring.” 

“My founding partner Dominik Sievert and I are very grateful that our investors put such great trust in us and our vision. Together we are working towards the goal of using our innovation capacities to develop technologies that can be put to serve people. We want to help lab technicians who give their best every day at labs and we want to ensure the safety of patients as well as the speed and reliability of the entire diagnostic process. That’s why we will use this further investment for our forthcoming series production and expansion into new markets,” says Managing Partner Maria Sievert. 

Currently, the IoT/SaaS integral system – consisting of a lab automation machine, an intelligent sample container, and AI-enhanced software – is being implemented with several customers in the D/A/CH region including well-known university clinics in Germany. The entry into further markets within and outside of Europe is planned for the later this year.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper